Top Dividend Stocks To Invest In 2016

Top Dividend Stocks To Invest In 2016: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 ! and is based in N e w Brunswick, New Jersey.

Advisors' Opinion:

• [By WALLSTCHEATSHEET]

  Johnson & Johnson provides health care products in a variety of stages to consumers and medical businesses around the world. The stock has been in an excellent uptrend in recent times and is now trading at all-time high prices. Revenue figures have been steadily rising while earnings have been mixed, regardless, investors have been pleased. Relative to its peers and sector, Johnson & Johnson has led in year-to-date performance by a significant spread. Look for Johnson & Johnson to continue to OUTPERFORM.

• [By Paul Ausick]

  The other healthcare stock leading the DJIA today was Johnson & Johnson (NYSE: JNJ), which posted a gain of 2.13% to close at $94.30 in a 52-week range of $71.25 to $95.99. RBS Capital upgraded J&Js shares to Outperform this morning citing specifically the companys rising pharmaceuticals business. Volume was about 23% above the daily average of 7.1 million shares.

• [By Dan Carroll]

  Take a look around the top device companies reporting this week, and you'll see a picture of lackluster growth. Johnson & Johnson (NYSE: JNJ  ) , one of the biggest names in health care, saw double-digit growth from its medical device department, but only because of its $12 billion acquisition of orthopedics powerhouse Synthes last year. Fellow diversified medical firm Abbott Labs' (NYSE: ABT  ) medical device sales fell more than 4% despite its dominant position in the stent industry. St. Jude Medical (NYSE: STJ  ) also saw sales decline 3% at a constant currency, even as the company managed to grow earnings by more than 5% by cutting costs.

• [By Dividends4Life]

  There are a number of ways to invest successfully. I have friends who are very successful value investors. Most of their returns are earned through capital appreciation. They spend a great deal of ti! me pourin! g through 10-Ks and 10-Qs of companies off the beaten path. The potential returns are high, but so is the effort put in their craft. At the other extreme there are successful traders. They look at their charts to determine entry and exit points for the day's transactions. Little to no time is spent analyzing the underlying fundamentals of the company since it likely will only be held for a very short period of time. I would put investors in dividend growth stocks somewhere between these two, but much closer to the pure value investor. Like the value investors, our time-frame is long term. Although we carefully research potential companies, our emphasis leans more toward fundamental metrics needed to sustain annual dividend growth, with less emphasis on current value. There are successful investors in each of the above groups, and they share a common trait. This trait is found in most all successful people it is their secret to success. Fortunately, this trait can be learned and mastered. The secret to successful investing is... discipline. A person that moves from one investment strategy to another lacks the discipline to be successful. Very few people are born with the raw intellect that allows them to just pick winning stocks out of the air. For the rest of us, we have to rely on our discipline to do what's necessary to identify stocks that will provide us with our best opportunity to succeed, and we have to remain focused on quality over the long-term. Our portfolios include stocks like:Emerson Electric Co. (EMR) | Yield: 2.5% Emerson Electric Co. designs and supplies product technology and delivers engineering services and solutions to a wide range of industrial, commercial and consumer markets around the world. The company has paid a cash dividend t

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-dividend-stocks-to-invest-in-2016.html